Wall Street Stock Recommendations: Valero Energy Corporation (VLO), Sierra Oncology, Inc. (SRRA)

Valero Energy Corporation (NYSE:VLO) was less active in the last trading session as around 3.12 million shares exchanged hands on Wall Street, representing a decrease from its normal capacity of 3.68 million shares. A 0.14% change after the initial price of $80.89, sent the closing price to $81.48.

Valero Energy Corporation (VLO) Analyst Opinion

Valero Energy Corporation has a consensus outperform rating from 21 Wall Street analysts, and the number of shares currently sold short amount to at least 4.4% of shares outstanding. The stock spiked 4.97% last month and is up 19.26 this year. Wall Street is only getting more bullish on the stock, with 9 of analysts who cover VLO having a buy-equivalent rating. Analysts have placed a $82.11 price target on Valero Energy Corporation, suggesting a 0.77% gain from recent close. It’s currently trading about -0.86% below its 52-week high.

Valero Energy Corporation Earnings Surprise

Valero Energy Corporation (VLO) surprised the stock market in its last reported earnings when it earned $1.91 a piece versus the consensus-estimated $1.83. Its revenue totaled $19.03 billion down -14.47% from the previous quarter.

Valero Energy Corporation (NYSE:VLO) Intraday View

This stock (VLO) is ahead of its 52-week low with 35.01%. Its last month’s stock price volatility remained 1.43% which for the week stands at 1.51%. The share price has moved forward from its 20 days moving average, trading at a distance of 2.51% and stays 6.55% away from its 50 days moving average. Over the last five days, shares have faced -0.23% losses and now is up 18.5% since hitting its 200-day moving average of $69.83. Valero Energy Corporation (VLO) has made its way to a 12-month gain of 29.03%.

Turning to Sierra Oncology, Inc. (NASDAQ:SRRA), its shares were trading at $1.96 a gain of $0.02, on the trading floor. The stock, after opening at $1.95, touched a high of $2.07 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.3. Sierra Oncology, Inc. has 2 buy ratings, 0 holds and 0 sells even after the stock tumbled -12.89% from its high of $2.25 to a $102.45 million market value through last close.

Sierra Oncology, Inc. (SRRA) Consensus Price Target

The company’s consensus rating on Reuter’s scale slipped from 2 to 1.33 during a month. Analysts set a 12-month price target of $4.33 a share. The target implies a 120.92% spike from where the shares are currently trading. Also, the current price highlights a discount of 155.1% to analysts’ high consensus price target.

Sierra Oncology, Inc. (NASDAQ:SRRA) Intraday Trading

The counter witnessed a trading volume of 0.35 million shares versus an average volume of 0.32 million shares during last trading session. Its last month’s stock price volatility remained 6.81% which for the week approaches 8.72%. The lowest price the stock reached in the last trading day was $1.9406 and compares with the $1.10 52-week low. The stock recovered 78.18% since its low point and has performed 31.54% year-to-date.

Previous articleAnalysts Shared Their Read on 2 Stocks: The Sherwin-Williams Company (SHW), Vanda Pharmaceuticals Inc. (VNDA)
Next articleAnalyzing Stocks On Analyst Opinion: The Allstate Corporation (ALL), CytomX Therapeutics, Inc. (CTMX)